What is HC Wainwright’s Forecast for Invivyd Q1 Earnings?

Invivyd, Inc. (NASDAQ:IVVD) – Stock analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Invivyd in a note issued to investors on Wednesday, May 28th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright has a “Buy” rating and a $5.00 price objective on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Invivyd’s Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.08 EPS and FY2028 earnings at $0.18 EPS.

Separately, D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Invivyd in a report on Friday, May 16th.

Invivyd Stock Up 12.0%

NASDAQ:IVVD opened at $0.95 on Thursday. Invivyd has a twelve month low of $0.35 and a twelve month high of $2.74. The company has a fifty day moving average of $0.64 and a 200-day moving average of $0.74. The firm has a market capitalization of $113.93 million, a P/E ratio of -0.48 and a beta of 0.40.

Invivyd (NASDAQ:IVVD) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.10). The business had revenue of $11.30 million during the quarter, compared to analysts’ expectations of $34.45 million.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IVVD. JPMorgan Chase & Co. grew its stake in Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock valued at $114,000 after acquiring an additional 222,375 shares during the period. Mithril II GP LP bought a new position in shares of Invivyd in the 4th quarter worth $4,981,000. Renaissance Technologies LLC acquired a new stake in Invivyd in the 4th quarter valued at $74,000. AQR Capital Management LLC increased its stake in Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Finally, Invesco Ltd. increased its stake in Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares in the last quarter. 70.36% of the stock is owned by institutional investors and hedge funds.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.